Scribe Therapeutics files for Nasdaq IPO, testing market appetite for early-stage gene-editing firms

Scribe Therapeutics announced it has filed a registration statement to list its shares on the Nasdaq, marking the company’s first step toward a public offering.

The filing highlights the growing interest in early-stage biotech companies, especially those focused on CRISPR-based gene-editing technologies.

Analysts see the move as a barometer of investor appetite for novel gene-editing platforms, though the company has not disclosed valuation targets or timing for the offering.

The IPO could provide Scribe with capital to advance its pipeline, while giving public markets a chance to invest in a firm at the forefront of genome-editing research.